Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2024 | Arterial Occlusive Disease | Research

Causal association between helicobacter pylori and atherosclerosis: a two-sample Mendelian randomization

Authors: Xueyi Zhang, Yue Shi, Tielin Li, Ke Chang, Yongyan Gan, Yue Feng, Xianhua Zhou

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Abstract

Background

Helicobacter pylori (H. pylori), according to a number of recent observational studies, is connected to atherosclerosis (AS). However, the link between H. pylori and AS is debatable.

Methods

In order to calculate the causal relationship between H. pylori and AS, we employed a two-sample Mendelian randomization (MR) analysis. The data for H. pylori were obtained from the IEU GWAS database (https://gwas.mrcieu.ac.uk/datasets/) and the data for AS were obtained from the Finngen GWAS database (https://r5.finngen.fi/). We selected single nucleotide polymorphisms with a threshold of 5 × 10^–6 from earlier genome-wide association studies. MR was performed mainly using the inverse variance weighted (IVW) method. To ensure the reliability of the findings, We performed a leave-one-out sensitivity analysis to test for sensitivity. F-value was used to test weak instrument.

Results

A positive causal relationship between H. pylori OMP antibody levels and peripheral atherosclerosis was shown by our two-sample MR analysis (odds ratio (OR) = 1.33, 95% confidence interval (CI) = 1.14–1.54, P = 0.26E-03) using IVW. Additionally, there was a causative link between coronary atherosclerosis and H. pylori VacA antibody levels (IVW OR = 1.06, 95% CI = 1.01–1.10, P = 0.016). All the F-values were above 10.

Conclusions

This MR study discovered a causal link between H. pylori and AS. Different antibodies have different effects, so future researches are needed to figure out the exact mechanisms behind this link.

Available only for authorised users

Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868–76. https://doi.org/10.1111/apt.14561.CrossRefPubMed

Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553–64. https://doi.org/10.1016/S2468-1253(23)00070-5.CrossRefPubMed

Cesaro A, Bianconi V, Gragnano F, Moscarella E, Fimiani F, Monda E, Scudiero O, Limongelli G, Pirro M, Calabrò P. Beyond cholesterol metabolism: the pleiotropic effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. BioFactors. 2020;46(3):367–80. https://doi.org/10.1002/biof.1619.CrossRefPubMed

He C, Yang Z, Lu N-H. Helicobacter pylori—an infectious risk factor for atherosclerosis? J Atheroscler Thromb. 2014;21(12):1229–42. https://doi.org/10.5551/jat.25775.CrossRefPubMed

Shi H, Li Y, Dong C, Si G, Xu Y, Peng M, Li Y. Helicobacter pylori infection and the progression of atherosclerosis: a systematic review and meta-analysis. Helicobacter. 2022;27(1):e12865. https://doi.org/10.1111/hel.12865.CrossRefPubMed

Björkegren JL, Lusis AJ. Atherosclerosis: recent developments. Cell. 2022;185(10):1630–45. https://doi.org/10.1016/j.cell.2022.04.004.CrossRefPubMedPubMedCentral

Butler-Laporte G, Kreuzer D, Nakanishi T, Harroud A, Forgetta V, Richards JB. Genetic determinants of antibody-mediated immune responses to infectious diseases agents: a genome-wide and HLA association study. Open Forum Infect Dis. 2020;7(11):ofaa450. https://doi.org/10.1093/ofid/ofaa450.CrossRefPubMedPubMedCentral

Long Y, Tang L, Zhou Y, Zhao S, Zhu H. Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study. BMC Med. 2023;21(1):66. https://doi.org/10.1186/s12916-023-02761-6.CrossRefPubMedPubMedCentral

Zou X-L, Wang S, Wang L-Y, Xiao L-X, Yao T-X, Zeng Y, Zhang L. Childhood obesity and risk of stroke: a Mendelian randomisation analysis. Front Genet. 2021;12:727475. https://doi.org/10.3389/fgene.2021.727475.CrossRefPubMedPubMedCentral

10.

Huang JY, Labrecque JA. From GWAS to PheWAS: the search for causality in big data. Lancet Digit Health. 2019;1(3):e101–3. https://doi.org/10.1016/S2589-7500(19)30059-7.CrossRefPubMed

11.

Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658–65. https://doi.org/10.1002/gepi.21758.CrossRefPubMedPubMedCentral

12.

Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM, Davey Smith G, Gaunt TR, Haycock PC. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408. https://doi.org/10.7554/eLife.34408.CrossRefPubMedPubMedCentral

13.

Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method for Mendelian randomization with hundreds of genetic variants. Nat Commun. 2020;11(1):376. https://doi.org/10.1038/s41467-019-14156-4.ADSCrossRefPubMedPubMedCentral

14.

Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the i2 statistic. Int J Epidemiol. 2016;45(6):1961–74. https://doi.org/10.1093/ije/dyw220.CrossRefPubMedPubMedCentral

15.

Du L, Liu J, Jin C, Ma Y, Yin L, Man S, Li S, Li L, Ning Y, Zhang X. Association between helicobacter pylori infection and carotid atherosclerosis in Chinese adults. Atheroscler Plus. 2021;44:25–30. https://doi.org/10.1016/j.athplu.2021.08.004.CrossRefPubMedPubMedCentral

16.

Zhang L, Chen Z, Xia X, Chi J, Li H, Liu X, Li R, Li Y, Liu D, Tian D, Wang H, Petroski GF, Flaker GC, Hao H, Liu Z, Xu C. Helicobacter pylori infection selectively increases the risk for carotid atherosclerosis in young males. Atherosclerosis. 2019;291:71–7. https://doi.org/10.1016/j.atherosclerosis.2019.10.005.CrossRefPubMedPubMedCentral

17.

Guo Y, Xu C, Zhang L, Chen Z, Xia X. Helicobacter pylori infection acts as an independent risk factor for intracranial atherosclerosis in women less than 60 years old. Front Cardiovasc Med. 2021;8:819315. https://doi.org/10.3389/fcvm.2021.819315.CrossRefPubMed

18.

Keikha M, Karbalaei M. A comprehensive survey of the relationship between helicobacter pylori infection and atherosclerosis in the Iranian population: a systematic review and meta-analysis. Arch Iran Med. 2022;25(4):257–66. https://doi.org/10.34172/aim.2022.42.CrossRefPubMed

19.

Li B, Xia Y, Hu B. Infection and atherosclerosis: TLR-Dependent pathways. Cell Mol Life Sci. 2020;77(14):2751–69. https://doi.org/10.1007/s00018-020-03453-7.CrossRefPubMedPubMedCentral

20.

Hagiwara N, Toyoda K, Inoue T, Shimada H, Ibayashi S, Iida M, Okada Y. Lack of association between infectious burden and carotid atherosclerosis in Japanese patients. J Stroke Cerebrovasc Dis. 2007;16(4):145–52. https://doi.org/10.1016/j.jstrokecerebrovasdis.2007.02.001.CrossRefPubMed

21.

Pilotto A, Rumor F, Franceschi M, Leandro G, Novello R, Soffiati G, Scagnelli M, Di Mario F, Valerio G. Lack of association between helicobacter pylori infection and extracardiac atherosclerosis in dyspeptic elderly subjects. Age Ageing. 1999;28(4):367–71. https://doi.org/10.1093/ageing/28.4.367.CrossRefPubMed

22.

The causal effect of Helicobacter pylori infection on coronary heart disease is mediated by the body mass index: a Mendelian randomization study | Scientific Reports. https://www.nature.com/articles/s41598-024-51701-8. Accessed 2024–02–09.

23.

Wernly S, Semmler G, Völkerer A, Flamm M, Aigner E, Niederseer D, Wernly B, Datz C. Helicobacter pylori and cardiovascular risk: only a dead helicobacter is a good helicobacter? Helicobacter. 2022;27(6):e12928. https://doi.org/10.1111/hel.12928.CrossRefPubMedPubMedCentral

24.

Xu Z, Li J, Wang H, Xu G. Helicobacter pylori infection and atherosclerosis: is there a causal relationship? Eur J Clin Microbiol Infect Dis. 2017;36(12):2293–301. https://doi.org/10.1007/s10096-017-3054-0.CrossRefPubMed

25.

Wang Q, Liu Y, Xu Z, Wang Z, Xue M, Li X, Wang Y. Causality of anti-helicobacter pylori igg levels on myocardial infarction and potential pathogenesis: a Mendelian randomization study. Front Microbiol. 2023;14:1259579. https://doi.org/10.3389/fmicb.2023.1259579.CrossRefPubMedPubMedCentral

26.

Odenbreit S, Swoboda K, Barwig I, Ruhl S, Borén T, Koletzko S, Haas R. Outer membrane protein expression profile in helicobacter pylori clinical isolates. Infect Immun. 2009;77(9):3782–90. https://doi.org/10.1128/IAI.00364-09.CrossRefPubMedPubMedCentral

27.

Xia J, Fang M, Wu X, Yang Y, Yu L, Xu H, Kong H, Tan Q, Wang H, Xie W, Xu Y. A2b adenosine signaling represses CIITA transcription via an epigenetic mechanism in vascular smooth muscle cells. Biochim Biophys Acta. 2015;1849(6):665–76. https://doi.org/10.1016/j.bbagrm.2015.03.001.CrossRefPubMed

28.

Cao Z, Wu Y, Li Q, Li Y, Wu J. A causal relationship between childhood obesity and risk of osteoarthritis: results from a two-sample Mendelian randomization analysis. Annals of medicine (Helsinki). 2022;54(1):1636–45. https://doi.org/10.1080/07853890.2022.2085883.CrossRef

29.

Munafò MR, Higgins JPT, Smith GD. Triangulating evidence through the inclusion of genetically informed designs. Cold Spring Harb Perspect Med. 2021;11(8):a040659. https://doi.org/10.1101/cshperspect.a040659.CrossRefPubMedPubMedCentral

Title: Causal association between helicobacter pylori and atherosclerosis: a two-sample Mendelian randomization
Authors: Xueyi Zhang
Yue Shi
Tielin Li
Ke Chang
Yongyan Gan
Yue Feng
Xianhua Zhou
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Arterial Occlusive Disease
Helicobacter Pylori
Published in: BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-024-03823-0

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Causal association between helicobacter pylori and atherosclerosis: a two-sample Mendelian randomization

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Serum levels of lipoprotein-associated phospholipase A2 are associated with coronary atherosclerotic plaque progression in diabetic and non-diabetic patients

Clinical comparative analysis of 3D printing-assisted extracorporeal pre-fenestration and Castor integrated branch stent techniques in treating type B aortic dissections with inadequate proximal landing zones

The association between C-reactive protein and coronary artery calcification: a systematic review and meta-analysis

Effects on physical activity, physical fitness and well-being in a 36-months randomized controlled study, comparing a multimodal hospital-based intervention programme for primary cardiovascular prevention with usual care

Effects of staged rehabilitation training on inflammatory factor levels and red blood cell distribution width followingcardiac valve replacement

Predictors for new-onset conduction block in patients with pure native aortic regurgitation after transcatheter aortic valve replacement with a new-generation self-expanding valve (VitaFlow Liberty™): a retrospective cohort study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page